Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | BID | P55957 | 3/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.42 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.42 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30150434 | 0.80 | BID (0.50) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL29763191 | 0.80 | BID (0.50) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL26622817 | 0.80 | BID (0.50) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL15512094 | 0.80 | BID (0.50) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL23748542 | 0.80 | BID (0.50) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL5138373 | 0.80 | KCNH2 (0.43) | ALDH1A1ATMGCGR | |
| SCHEMBL14989208 | 0.78 | BID (0.49) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL9718193 | 0.78 | BID (0.49) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL63310 | 0.78 | BID (0.49) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL21385065 | 0.78 | BID (0.49) | BIDMCL1BCL2L1BAK1KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143954-B1 | USE OF NICOTINIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIV KENTUCKY RES FOUND (US) | 2004-08-11 | — | — | EP | claimed |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2004-07-29 | — | — | US | claimed |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2001-10-25 | — | — | US | claimed |
| EP-1143954-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | University of Kentucky Research Foundation (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000032179-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2000-06-08 | — | — | WO | claimed |
| US-7425319-B2 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1143954-B1 | USE OF NICOTINIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIV KENTUCKY RES FOUND (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6552050-B2 | Adjustment of cellular nicotinamide-adenine dinucleotide | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-04-22 | — | — | US | disclosed |
| US-20020123517-A1 | Reducing cell necrosis or apoptosis by administering a pro-NAD compound such as nicotinic acid or nicotinamide; nicotinamide adenine dinucleotide (NAD); manipulating poly(ADP-ribose) polymerase pathways | JACOBSON ELAINE L (US) | 2002-09-05 | — | — | US | disclosed |
| US-6403619-B1 | TOPICALLY ADMINISTERING PRO-NAD COMPOUND (ESTERS OF NICOTINIC ACID) | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2002-06-11 | — | — | US | disclosed |
| US-6337065-B1 | FOR THERAPY OF DISORDERS SUCH AS SUNBURN AND OTHER SKIN DETERIORATION THAT RESULTS FROM DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2002-01-08 | — | — | US | disclosed |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NIADYNE, INC. | 2001-10-25 | — | — | US | disclosed |
| EP-1143954-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | University of Kentucky Research Foundation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000032179-A2 | USE OF NICOTONIC ACID DERIVATIVES FOR THE TREATMENT OF DNA DAMAGE IN SKIN CELLS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123517-A1 | Reducing cell necrosis or apoptosis by administering a pro-NAD compound such as nicotinic acid or nicotinamide; nicotinamide adenine dinucleotide (NAD); manipulating poly(ADP-ribose) polymerase pathways | NAMPT, NADK, NAPRT | DPP4 2623/4885BID 125/4885MCL1 431/4885 |
| US-20040147491-A1 | Prevent, maintenance of Dna damage; administering compound which forms nicotinamide-adenine dinucleotide | NQO1, NNT, NAMPT | DPP4 3314/4885BID 553/4885MCL1 2280/4885 |
| US-20010033848-A1 | Adjustment of cellular nicotinamide-adenine dinucleotide | NQO1, NNT, NAMPT | DPP4 3039/4885BID 1152/4885MCL1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.